CLINICAL TRIALS PROFILE FOR MONISTAT 1 COMBINATION PACK
✉ Email this page to a colleague
All Clinical Trials for MONISTAT 1 COMBINATION PACK
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01661556 ↗ | Clinical Trial of Hydroquinone Versus Miconazol in Melasma | Unknown status | Hospital Central "Dr. Ignacio Morones Prieto" | Phase 4 | 2011-10-01 | Melasma is an acquired discoloration of the skin characterized by brown colour changes commonly on the face.The duration of this double-blind clinical trial will be 12 weeks. The control group will receive treatment with topical Hydroquinone (4%), and the other group topical miconazole. Miconazol has antimelanotic properties and can be used as treatment for melasma patients. The estimated number of subjects to be recruited and randomized for the study is at least 30. The purpose of this study is determine if there is a difference in the effectiveness of these two agents. Melasma Area and Severity Index (MASI) score will be assessed at the beginning of the study and at weeks 4, 8, and 12. Photographs, colorimetry and histological assessment will be also evaluated. Occurrence of adverse effects will also be recorded. |
| NCT01661556 ↗ | Clinical Trial of Hydroquinone Versus Miconazol in Melasma | Unknown status | Universidad Autonoma de San Luis Potosí | Phase 4 | 2011-10-01 | Melasma is an acquired discoloration of the skin characterized by brown colour changes commonly on the face.The duration of this double-blind clinical trial will be 12 weeks. The control group will receive treatment with topical Hydroquinone (4%), and the other group topical miconazole. Miconazol has antimelanotic properties and can be used as treatment for melasma patients. The estimated number of subjects to be recruited and randomized for the study is at least 30. The purpose of this study is determine if there is a difference in the effectiveness of these two agents. Melasma Area and Severity Index (MASI) score will be assessed at the beginning of the study and at weeks 4, 8, and 12. Photographs, colorimetry and histological assessment will be also evaluated. Occurrence of adverse effects will also be recorded. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MONISTAT 1 COMBINATION PACK
Condition Name
Clinical Trial Locations for MONISTAT 1 COMBINATION PACK
Clinical Trial Progress for MONISTAT 1 COMBINATION PACK
Clinical Trial Phase
Clinical Trial Sponsors for MONISTAT 1 COMBINATION PACK
Sponsor Name
